BioWorld

April 27, 2006

HIV Study Adding African Site For Targeted Genetics' Product

HIV researchers are enlisting a gene therapy product in an expanding study that's under way in southern Africa. (BioWorld Today) Read More

Alkermes Starts Phase III Of Inhaled Insulin Product

FivePrime, BI Enter Deal In RA Worth Up To $75M

For Replikins, Replication Data Allow For Predicting Epidemics

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

ASH 2025: Ianalumab data offer break from chronic ITP therapy

BioWorld

Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...